CollPlant Biotechnologies announced on June 4, 2025, that the European Patent and Trademark Office has allowed a patent application related to its injectable fillers and regenerative breast implant candidates. This patent provides further protection in Europe, a key strategic market for the company.
The newly allowed patent application specifically pertains to CollPlant's injectable soft tissue fillers and its organ manufacturing technology for regenerative breast implants. It covers a 3D biocompatible and degradable soft tissue implant composed of a bioprinted scaffold and an injectable filler, both based on recombinant human collagen (rhCollagen).
This patent is effective until 2041 and is an integral part of CollPlant's strategy to expand the uses for its novel rhCollagen technology into high-value markets. The market for injectable soft-tissue fillers is estimated at over $6 billion annually, and the addressable market for breast implants is over $3 billion annually.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.